13/07/2018 01:00:00

Precision Therapeutics Granted European Patent for its Automated, Direct-to-Drain Medical Fluid Disposal System

MINNEAPOLIS , July 12, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, is pleased to announce that on July 11, 2018 the European Patent Office (“EPO”) granted European Patent No. 2948200  covering the Company’s STREAMWAY® System for automated, direct-to-drain medical fluid disposal, which is sold through the Company’s Skyline Medical division.

The Company is seeking national validation of its European patent in 11 European countries, including Belgium, France, Germany, Ireland, Italy, the Netherlands, Norway, Poland, Spain, Sweden and the United Kingdom. As a result of the granting of the European patent, the Company has confidence that its intellectual property is protected as it executes on its sales strategy for its revolutionary, CE-marked, STREAMWAY System in Europe.

Dr. Carl Schwartz, Chief Executive Officer of Precision Therapeutics, commented, “We view this announcement as recognition of the unique benefits of the STREAMWAY System and validation of our belief that we have a one-of-a-kind offering that fulfils an unmet need in Europe. Our international expansion strategy is underway, led by our European Headquarters, which opened earlier this year, and supported by our strong team of in-house sales reps and local independent distributors. As we continue to grow our presence in Europe, we are pleased to have this patent in place to provide protection for our product.”

The STREAMWAY System is a true direct-to-drain fluid disposal system designed specifically for medical applications, such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY System connects directly to a facility's plumbing system to automate the collection, measurement and disposal of waste fluids. This minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. It also provides unlimited capacity for increased efficiency in the operating room, which leads to greater profitability. Furthermore, the STREAMWAY System eliminates the need for canisters – thereby reducing overhead costs and providing greater environmental stewardship by helping eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the U.S.

For a demonstration please visit www.skylinemedical.com or call 855-785-8855.

To be added to the Precision Therapeutics’ database, please email Info@MoneyInfo-llc.com with your email address.  This is solely for the use of Precision Therapeutics and will not be sold or distributed to third parties.

About Precision Therapeutics Inc.

Precision Therapeutics (NASDAQ:AIPT) operates in two business areas: first, applying artificial intelligence to personalized medicine and drug discovery to provide personalized medicine solutions for patients and clinicians as well as clients in the pharmaceutical, diagnostic, and biotech industries, and second, production of the FDA-approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal. For additional information, please visit www.precisiontherapeutics.com.

Precision Therapeutics’ medicine business is committed to improving the effectiveness of cancer therapy using the power of artificial intelligence (AI) applied to rich data diseases databases. This business has launched with Precision Therapeutics' investment in Helomics Corporation, a precision medicine company and integrated clinical contract research organization whose mission is to improve patient care by partnering with pharmaceutical, diagnostic, and academic organizations to bring innovative clinical products and technologies to the marketplace.  In addition to its proprietary precision diagnostics for oncology, Helomics offers boutique CRO services that leverage their patient-derived tumor models, coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and a proprietary bioinformatics platform (D-CHIP) to provide a tailored solution to our client's specific needs. Helomics is 25% owned by Precision Therapeutics.  Helomics® is headquartered in Pittsburgh, Pennsylvania where the company maintains state-of-the-art, CLIA-certified, clinical and research laboratories. For more information, please visit www.Helomics.com

Precision Therapeutics has also announced the formation of a subsidiary, TumorGenesis to pursue a new rapid approach to growing tumors in the laboratory, which essentially “fools” the cancer cells into thinking they are still growing inside the patient. Precision Therapeutics and Helomics have also announced a proposed joint venture with GLG Pharma focused on using their combined technologies to bring personalized medicines and testing to ovarian and breast cancer patients, especially those who present with ascites fluid (over one-third of patients). The growth strategy in this business includes securing new partnerships and considering acquisitions in the precision medicine space.

Sold through the Skyline Medical business of Precision Therapeutics, The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid and other potentially infectious fluids found in the healthcare environment. Antiquated manual fluid handling methods that require hand carrying and emptying filled fluid canisters present an exposure risk and potential liability. Skyline Medical's STREAMWAY System fully automates the collection, measurement, and disposal of waste fluids and is designed to: 1) reduce overhead costs to hospitals and surgical centers; 2) improve compliance with OSHA and other regulatory agency safety guidelines; 3) improve efficiency in the operating room, and radiology and endoscopy departments, thereby leading to greater profitability; and 4) provide greater environmental stewardship by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills each year in the U.S.  For additional information, please visit www.skylinemedical.com.

Forward-looking Statements

Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include (1) risks related to the proposed merger, including the fact that we may not complete the merger; we do not have complete information about Helomics; the combined company will not be able to continue operating without additional financing; possible failure to realize anticipated benefits of the merger; costs associated with the merger may be higher than expected; the merger may result in disruption of the Company’s and Helomics’ existing businesses, distraction of management and diversion of resources; delay in completion of the merger may significantly reduce the expected benefits; and the market price of the Company’s common stock may decline as a result of the merger; (2) risks related to our partnerships with other companies, including the need to negotiate the definitive agreements; possible failure to realize anticipated benefits of these partnerships; and costs of providing funding to our partner companies, which may never be repaid or provide anticipated returns; and (3) other risks and uncertainties relating to the Company that include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; sales cycles that can be longer than expected, resulting in delays in projected sales or failure to make such sales; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance, if our product is not accepted by our potential customers, it is unlikely that we will ever become profitable; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission, which are available for review at www.sec.gov.  This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position. See the Company's most recent Annual Report on Form 10-K, and subsequent reports and other filings at www.sec.gov.

Contacts:

Investor Relations

KCSA Strategic Communications

Elizabeth Barker

(212) 896-1203

ebarker@kcsa.com

MONEYINFO, LLC

Charles Moskowitz

617-827-1296

info@moneyinfo-llc.com 

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
15 Jul
VWS
  Her i sommervarmen har jeg kigget lidt på Vestas kvartalsregnskaber og udviklingen i driftsmargine..
45
18 Jul
ZEAL
Baronen du er kandidat til stoerste selvfede narrehat herinde, uanset hvor mange gange du gentager d..
21
17 Jul
EI
Kære brugere   Som i har bemærket, er der igen til morgen problemer med vores streaming. Realtidskur..
17
16 Jul
DANSKE
Har du fået nej til en kassekredit nede i Danske Bank ?
17
17 Jul
VWS
MHI Vestas har nu øget sin ordrebeholdning til over 5GW, og der kommer meget mere endnu, og til næst..
16
17 Jul
 
USA har den svageste og mest retarderede præsident, som de nogensinde har haft.
14
19 Jul
GOOGL
Trump er uduelig og Putin benytter alle muligheder for at sætte splid internt i US og alle andre ste..
12
18 Jul
ZEAL
Ja, du har sagt og skrevet meget, og da det ikke er bedre end nedenfor, så har det ikke den store ef..
12
18 Jul
 
Dine reklamer afspejler din ageren på nettet. Tak dig selv for dine kinesiske reklamer
11
19 Jul
 
Hej Paknet. Æhæm, altså, hvordan skal jeg skære denne kage? Du ER tydeligvis ny på markedet, og der ..
10

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Second quarter 2018 results - ramping up construction and increasing backlog and pipeline
2
Pittsburgh International Airport Selects World-Renowned Architectural and Engineering Firms with Local Ties to Collaborate on Design of New Terminal
3
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against National Beverage Corp.
4
Sterling National Bank Grows Commercial Banking and Commercial Finance Teams with Key Hires
5
FAURECIA : DOUBLE-DIGIT GROWTH IN SALES AND OPERATING INCOME IN THE FIRST HALF - UPGRADED FULL-YEAR GUIDANCE

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
21 July 2018 04:59:39
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180712.1 - EUROWEB2 - 2018-07-21 05:59:39 - 2018-07-21 04:59:39 - 1000 - Website: OKAY